Cancers, Vol. 16, Pages 848: Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?
Gatta
Artificial intelligence (AI) is emerging as a discipline capable of providing significant added value in Medicine, in particular in radiomic, imaging analysis, big dataset analysis, and also for generating virtual cohort of patients. However, in coping with chronic myeloid leukemia (CML), considered an easily managed malignancy after the introduction of TKIs which strongly improved the life expectancy of patients, AI is still in its infancy. Noteworthy, the findings of initial trials are intriguing and encouraging, both in terms of performance and adaptability to different contexts in which AI can be applied. Ind...
Source: Cancers - February 20, 2024 Category: Cancer & Oncology Authors: Simona Bernardi Mauro Vallati Roberto Gatta Tags: Review Source Type: research
Pharmacokinetics of Dasatinib in Rats: a Potential Food –Drug Interaction with Naringenin
ConclusionConcurrent use of naringenin-containing supplements, herbs, or foods with dasatinib may cause serious and potentially life-threatening drug interactions. Further studies are necessary to determine the clinical significance of these findings. (Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - February 20, 2024 Category: Drugs & Pharmacology Source Type: research
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research
NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment
Immunology. 2024 Feb 15. doi: 10.1111/imm.13768. Online ahead of print.ABSTRACTNatural killer (NK) cell is a valuable tool for immunotherapy in cancer treatment, both the cultured cell line NK92 and primary NK cells are widely studied and used in research and clinical trials. Clinical observations witnessed the improvement of patients' NK cells in terms of cell counts and cytotoxic activity upon dasatinib treatment, an approved drug for chronic myeloid leukaemia and Ph+ acute lymphocytic leukaemia. Several studies supported the clinical observations, yet others argued a detrimental effect of dasatinib on NK cells. Due to t...
Source: Immunology - February 16, 2024 Category: Allergy & Immunology Authors: Fengqi Li Zhongyi Wang Dongpeng Zheng Zhaojun Pang Chunjing Feng Yue Ma Ce Yang Xueren Li Shouchun Peng Zichuan Liu Xin Mu Source Type: research
Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India
This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance. During the study period from 2018 to 2022 (48 months), the blood samples from 219 Reverse transcriptase-PCR-confirmed CML patients following RNA extraction and cDNA preparation were subjected to M351T, E255K, and Y253H mutation analysis by PCR-RFLP. After agarose gel visualization, the samples were subjected to Sanger sequencing to confirm the nucleotide change at the polymorphic loci. The wild-type genotype of all three ABL1 SNPs under investigation exhibits a significant reduction in frequency amo...
Source: Biochemical Genetics - February 16, 2024 Category: Genetics & Stem Cells Authors: Gautam Hazarika Manash Jyoti Kalita Partha Pratim Das Simanta Kalita Kalpajit Dutta Lipika Lahkar Anjanjyoti Rajkonwar Mohammed Ghaznavi Idris Vinotsale Khamo Giriraj Kusre Subhash Medhi Source Type: research
NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment
Immunology. 2024 Feb 15. doi: 10.1111/imm.13768. Online ahead of print.ABSTRACTNatural killer (NK) cell is a valuable tool for immunotherapy in cancer treatment, both the cultured cell line NK92 and primary NK cells are widely studied and used in research and clinical trials. Clinical observations witnessed the improvement of patients' NK cells in terms of cell counts and cytotoxic activity upon dasatinib treatment, an approved drug for chronic myeloid leukaemia and Ph+ acute lymphocytic leukaemia. Several studies supported the clinical observations, yet others argued a detrimental effect of dasatinib on NK cells. Due to t...
Source: Immunology - February 16, 2024 Category: Allergy & Immunology Authors: Fengqi Li Zhongyi Wang Dongpeng Zheng Zhaojun Pang Chunjing Feng Yue Ma Ce Yang Xueren Li Shouchun Peng Zichuan Liu Xin Mu Source Type: research
Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India
This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance. During the study period from 2018 to 2022 (48 months), the blood samples from 219 Reverse transcriptase-PCR-confirmed CML patients following RNA extraction and cDNA preparation were subjected to M351T, E255K, and Y253H mutation analysis by PCR-RFLP. After agarose gel visualization, the samples were subjected to Sanger sequencing to confirm the nucleotide change at the polymorphic loci. The wild-type genotype of all three ABL1 SNPs under investigation exhibits a significant reduction in frequency amo...
Source: Biochemical Genetics - February 16, 2024 Category: Genetics & Stem Cells Authors: Gautam Hazarika Manash Jyoti Kalita Partha Pratim Das Simanta Kalita Kalpajit Dutta Lipika Lahkar Anjanjyoti Rajkonwar Mohammed Ghaznavi Idris Vinotsale Khamo Giriraj Kusre Subhash Medhi Source Type: research
Clinico-hematological and immunophenotypic profile of acute leukemia of ambiguous lineage: A four year experience from a single tertiary care centre of West India
CONCLUSION: ALAL is overall associated with poor prognosis as both their diagnosis and treatment decisions are difficult owing to the lack of optimum treatment data and the rarity of the disease. Hence, A careful diagnosis with the help of immunophenotyping is crucial.PMID:38358200 | DOI:10.4103/ijpm.ijpm_59_22 (Source: Indian Journal of Pathology and Microbiology)
Source: Indian Journal of Pathology and Microbiology - February 15, 2024 Category: Pathology Authors: Varnika Rai Beena Brahmbhatt Anurag Saha Immanuel P Thayakaran Source Type: research
CX ‑5461 potentiates imatinib‑induced apoptosis in K562 cells by stimulating < em > KIF1B < /em > expression
In conclusion, the results suggested that the synergistic interaction between CX-5461 and imatinib may be of potential clinical value for the treatment of tyrosine kinase inhibitor-resistant chronic myeloid leukemia.PMID:38356673 | PMC:PMC10865453 | DOI:10.3892/etm.2024.12395 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - February 15, 2024 Category: General Medicine Authors: Chaochao Dai Xiaopei Cui Jie Wang Bo Dong Haiqing Gao Mei Cheng Fan Jiang Source Type: research
Clinico-hematological and immunophenotypic profile of acute leukemia of ambiguous lineage: A four year experience from a single tertiary care centre of West India
CONCLUSION: ALAL is overall associated with poor prognosis as both their diagnosis and treatment decisions are difficult owing to the lack of optimum treatment data and the rarity of the disease. Hence, A careful diagnosis with the help of immunophenotyping is crucial.PMID:38358200 | DOI:10.4103/ijpm.ijpm_59_22 (Source: Indian Journal of Pathology and Microbiology)
Source: Indian Journal of Pathology and Microbiology - February 15, 2024 Category: Pathology Authors: Varnika Rai Beena Brahmbhatt Anurag Saha Immanuel P Thayakaran Source Type: research
CX ‑5461 potentiates imatinib‑induced apoptosis in K562 cells by stimulating < em > KIF1B < /em > expression
In conclusion, the results suggested that the synergistic interaction between CX-5461 and imatinib may be of potential clinical value for the treatment of tyrosine kinase inhibitor-resistant chronic myeloid leukemia.PMID:38356673 | PMC:PMC10865453 | DOI:10.3892/etm.2024.12395 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - February 15, 2024 Category: General Medicine Authors: Chaochao Dai Xiaopei Cui Jie Wang Bo Dong Haiqing Gao Mei Cheng Fan Jiang Source Type: research
Cancers, Vol. 16, Pages 791: Male Fertility and Fatherhood in Chronic Myeloid Leukemia: Current Understanding and Future Perspectives
li
Mohamed Yassin
Chronic myeloid leukemia (CML), while traditionally a disease of the elderly, has recently risen in incidence among younger patients. Hence, fertility concerns have emerged considering the disease process and treatments, especially with the current scarce and conflicting recommendations. This review explores the impact of CML treatments including the first-line tyrosine kinase inhibitors (TKIs) and other treatments on male fertility in chronic myeloid leukemia (CML) patients. The aim of this review was to compile the available evidence on male fertility to ultimately tailor treatment plans for male ...
Source: Cancers - February 15, 2024 Category: Cancer & Oncology Authors: Ahmed Adel Elsabagh Maria Benkhadra Ibrahim Elmakaty Abdelrahman Elsayed Basant Elsayed Mohamed Elmarasi Mohammad Abutineh Nabeel Mohammad Qasem Elrazi Ali Mohamed Yassin Tags: Review Source Type: research
